TY - JOUR
T1 - Mindfulness in migraine
T2 - A narrative review
AU - Wells, Rebecca Erwin
AU - Seng, Elizabeth K.
AU - Edwards, Robert R.
AU - Victorson, David E.
AU - Pierce, Charles R.
AU - Rosenberg, Lauren
AU - Napadow, Vitaly
AU - Schuman-Olivier, Zev
N1 - Funding Information:
E Seng has consulted for GlaxoSmithKline, Eli Lilly, and Click Therapeutics and has received travel funds from the American Psychological Association, the American Academy of Neurology, and the American Association of Pain Medicine Foundation. V Napadow has a financial interest in Cala Health which is licensing the RAVANS tVNS technology from MGH. V Napadow’s interests were reviewed and are managed by the Massachusetts General Hospital and Partners HealthCare in accordance with their institutional policies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or conflict with the subject matter or materials discussed in this manuscript apart from those disclosed.
Funding Information:
RE Wells is supported by the National Center for Complementary & Integrative Health (NCCIH) of the National Institutes of Health under [Award Number K23AT008406]. E Seng is supported by NIH NINDS [NSK23096107; PI: Seng]. V Napadow is funded by US National Institutes for Health (NIH), Office of the Director [OT2-OD023867]; National Center for Complementary and Integrative Health (NCCIH), NIH [P01-AT009965, R61-AT009306, R33-AT009306, R01-AT007550]; and National Institute for Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH [R01-AR064367]. Z Schuman-Olivier is funded by NIH NCCIH P01AT009965 (PI-Napadow). RR Edwards is funded by NIH NCCIH P01AT009965 (PI-Napadow) and PCORI [Award OPD-1601-33860]. The authors gratefully acknowledge the editorial assistance of Indra M. Newman, PhD at the Wake Forest Clinical and Translational Science Institute, funded by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001420.
Funding Information:
The authors gratefully acknowledge the editorial assistance of Indra M. Newman, PhD at the Wake Forest Clinical and Translational Science Institute, funded by the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through Grant Award Number UL1TR001420.
Publisher Copyright:
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/3/3
Y1 - 2020/3/3
N2 - Introduction: Migraine is the second leading cause of disability worldwide, yet many patients are unable to tolerate, benefit from, or afford pharmacological treatment options. Non-pharmacological migraine therapies exist, especially to reduce opioid use, which represents a significant unmet need. Mindfulness-based interventions (MBI) have potential as a non-pharmacological treatment for migraine, primarily through the development of flexible attentional capacity across sensory, cognitive, and emotional experiences. Areas covered: The authors review efficacy and potential mechanisms of MBIs for migraine, including mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT). Expert opinion: While most mindfulness research studies for migraine to date have been pilot trials, which are small and/or lacked rigor, initial evidence suggests there may be improvements in overall headache-related disability and psychological well-being. Many research questions remain to help target the treatment to patients most likely to benefit, including the ideal dosage, duration, delivery method, responder characteristics, and potential mechanisms and biomarkers. A realistic understanding of these factors is important for patients, providers, and the media. Mindfulness will not ‘cure’ migraine; however, mindfulness may be an important tool as part of a comprehensive treatment approach to help patients ‘mindfully’ engage in valued life activities.
AB - Introduction: Migraine is the second leading cause of disability worldwide, yet many patients are unable to tolerate, benefit from, or afford pharmacological treatment options. Non-pharmacological migraine therapies exist, especially to reduce opioid use, which represents a significant unmet need. Mindfulness-based interventions (MBI) have potential as a non-pharmacological treatment for migraine, primarily through the development of flexible attentional capacity across sensory, cognitive, and emotional experiences. Areas covered: The authors review efficacy and potential mechanisms of MBIs for migraine, including mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT). Expert opinion: While most mindfulness research studies for migraine to date have been pilot trials, which are small and/or lacked rigor, initial evidence suggests there may be improvements in overall headache-related disability and psychological well-being. Many research questions remain to help target the treatment to patients most likely to benefit, including the ideal dosage, duration, delivery method, responder characteristics, and potential mechanisms and biomarkers. A realistic understanding of these factors is important for patients, providers, and the media. Mindfulness will not ‘cure’ migraine; however, mindfulness may be an important tool as part of a comprehensive treatment approach to help patients ‘mindfully’ engage in valued life activities.
KW - Complementary and alternative medicine
KW - integrative medicine
KW - meditation
KW - migraine
KW - mind-body medicine
KW - mindfulness
KW - mindfulness-based cognitive therapy
KW - mindfulness-based intervention
KW - mindfulness-based stress reduction
UR - http://www.scopus.com/inward/record.url?scp=85079429762&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85079429762&partnerID=8YFLogxK
U2 - 10.1080/14737175.2020.1715212
DO - 10.1080/14737175.2020.1715212
M3 - Review article
C2 - 31933391
AN - SCOPUS:85079429762
SN - 1473-7175
VL - 20
SP - 207
EP - 225
JO - Expert Review of Neurotherapeutics
JF - Expert Review of Neurotherapeutics
IS - 3
ER -